Market News & Trends
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Revive Therapeutics Ltd. recently provided an update on the company’s US FDA Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of….
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio
Collegium Pharmaceutical, Inc. and BioDelivery Sciences International, Inc. recently announced a definitive agreement pursuant to which Collegium will acquire BDSI for….
Pardes Biosciences Presents Interim Clinical Data From Ongoing PBI-0451 Phase 1 Trial
Pardes Biosciences, Inc. recently announced interim clinical data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers has been made available to registered…
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention & Treatment of Influenza
Cidara Therapeutics, Inc. recently announced the US FDA has accepted its Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 –…
Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate & Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline
Decibel Therapeutics recently announced the presentation of preclinical data on its lead gene therapy product candidate, DB-OTO, as well as preclinical data highlighting the identification of proprietary, cell-selective promoters….
IsoPlexis’ Immune Monitoring Helps Identify Early Factors of Long COVID in Cell Publication
IsoPlexis Corporation recently announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium, in which researchers…
CureVac Doses First Participant in Phase 1 Study With Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration With GSK
CureVac N.V. recently announced it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed…
Denali Therapeutics Announces Continued Progress in DNL310 Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial
DNL310 is an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of MPS II (Hunter syndrome). ….
Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety & Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene
Opiant Pharmaceuticals, Inc. recently announced positive topline results from a multi-dose pharmacokinetic (PK) study for OPNT003, nasal nalmefene, an investigational treatment for opioid….
Dyadic & Phibro Animal Health Announce Exclusive License Agreement to Develop & Commercialize Animal Health Vaccine
Dyadic International, Inc. and Phibro Animal Health recently announced they have entered into an exclusive license agreement for a Phibro targeted disease. This agreement follows…
Berkshire Sterile to Offer Formulation, Lyophilization & Method Development Services
Berkshire Sterile Manufacturing (BSM) MA, has recently added formulation, lyophilization, and method development capabilities to complement their clients’ drug productions…..
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma
Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. recently announced positive in vivo data for PNV-5032, as a potential treatment for….
Charles River Laboratories Licenses Genedata Biologics
Genedata recently announced Charles River Laboratories International, Inc., has chosen Genedata Biologics to support their rapidly expanding global biopharma operations across multiple groups in the…
TriRx Completes Acquisition of Elanco Manufacturing Facility in Speke, UK
TriRx Pharmaceutical Services, LLC, a leading international CDMO, recently announced it has finalized and closed on its agreement with Elanco Animal Health Incorporated to acquire the ownership and operations of….
Regio Biosciences Enters License Agreement With AstraZeneca for Phase 2a Asset in Peripheral Artery Disease
Regio Biosciences recently announced it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic acting on reverse cholesterol….
SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive & Untreatable Tumors
SEngine Precision Medicine Inc. and Oncodesign recently announced the signature of a research collaboration agreement for R&D of a new personalized cancer treatment for aggressive and…..
Cognizant Announces Partnership With Medable to Deliver Strategy, Deployment & Support Services for Decentralized Clinical Trials
Cognizant recently announced a partnership with Medable Inc. to jointly deliver clinical research solutions based on Medable’s software-as-a-service platform for decentralized clinical trials. Cognizant will…
Bormioli Pharma Keeps on Innovating on Glass to Achieve a Better Performing & More Sustainable Product
As the celebrations for the International Year of Glass are currently underway in Geneva, Switzerland, Bormioli Pharma recently announced new research and innovation projects. Through…
Gattefossé Strengthens its CSR Approach & Reaches Two Major Milestones
In line with its CSR commitment, Gattefossé has received ISO 14001:2015 certification for its main production site in France and has been ranked in the…
Biomerica Announces Positive Topline Results From the Endpoint Clinical Trial
Biomerica, Inc. recently announced positive topline results from the endpoint clinical trial of its InFoods IBS diagnostic-guided therapy (DGT), with the trial showing statistically significant…